Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
2 evidence topics · 2 sources
Phase 3 dose in the Himalayas-1 registry record
Pharmaceutical form and unit strengths
No evidence found.
Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide
Product information and disease descriptionProduct descriptionProduct information
2 evidence topics · 2 sources
No evidence found.